PEPTONIC Aktie

 

Peptonic Medical AB (publ) ("Peptonic" or the "Company") publishes today, February 27, 2026, its year-end report for 2025. Key figures for the Group - Fourth quarter (October – December) · Sales of goods amounted to KSEK 3,539 (4,445). · Gross profit amounted to KSEK 2,165 (2,563), corresponding to a gross margin of 61 (58) percent. · Operating profit amounted to KSEK 998 (-26,749). · Earnings per share amounted to SEK 0.0000001 (-0.005).   Key figures for the Group - Twelve months (January – December) · Sales of goods amounted to KSEK 14,788 (26,891). · Gross...

Peptonic Medical AB (publ) (the “Company”) announces that the Company has terminated its agreement with Mangold Fondförvaltning AB regarding the assignment as liquidity provider. The purpose of the liquidity provider arrangement has been to promote liquidity in the Company's share, reduce volatility and facilitate trading. The Company assesses that the current trading and liquidity in the share are satisfactory and that the benefit of a liquidity provider is therefore limited. The liquidity provider arrangement ceased after the close of trading on 23 February 2026. For more information...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Peptonic Medical AB (publ) ("Peptonic" or the "Company") announces that the rights issue of units consisting of shares and warrants, which formed part of the restructuring measures under...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Peptonic Medical AB (publ) ("Peptonic" or the "Company") has, as previously announced, completed the rights issue of units consisting of shares and warrants with preferential rights for...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Peptonic Medical AB (publ) ("Peptonic" or the "Company") today announces the outcome of the rights issue of units, consisting of shares and warrants of series TO6, which formed part of...

Peptonic Medical AB (publ) (“the Company”) announces a changed date for the publication of the Q4 report and also the year-end report for 2025 from February 25, 2026 to February 27, 2026. For further information, please contact: Anna Linton, CEO, Peptonic Medical AB                                            Email: anna.linton@peptonicmedical.se                                                                                      Phone: +46 70-244 92 07 About Peptonic Medical AB                                         PEPTONIC medical AB (publ) is a pioneering Swedish Medical...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Today, 23 January 2026, is the last day of trading with the unit rights in Peptonic Medical AB's (publ) ("Peptonic" or the "Company") rights issue of units, consisting of shares and...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Today, 14 January 2026, the subscription period begins in Peptonic Medical AB (publ) (”Peptonic” or the “Company”) rights issue of units, consisting of shares and warrants, which forms...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Peptonic Medical AB (publ) (”Peptonic” or the “Company”) has prepared an EU growth prospectus (the “Prospectus”) in connection with the Company's forthcoming rights issue of units,...

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Uppsala District Court has dismissed the corporate reconstruction proceedings. The dismissal decision means that the corporate reconstruction is thereby formally and legally concluded. The conclusion of the reconstruction entails that the Company returns to ordinary operations and continues the implementation of the measures set out in the reconstruction plan. The dismissal decision will be made available on the Company's website: https://www.peptonicmedical.se/investerare/foretagsrekonstruktion-2025/ For further...

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Company's reconstruction plan, which was confirmed by the Uppsala District Court on 28 November 2025, has now become legally binding. As a result, the corporate reconstruction process has been concluded. The Company will now proceed with the implementation of the reconstruction measures set out in the reconstruction plan. The confirmed reconstruction measures include, among other things: · A directed set-off issue and a rights issue, both to be carried out within two months from the date on which the...

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) clarifies the next steps in the reconstruction process and when the Company's corporate reconstruction is expected to conclude, following the approval of the reconstruction plan by the Uppsala District Court on 28 November 2025. In connection with the court's decision, it was also determined that the corporate reconstruction will terminate on the date the reconstruction plan becomes legally binding. The decision to approve the reconstruction plan replaces the District Court's previous decision to extend the corporate reconstruction...

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Uppsala District Court has decided to approve the Company's reconstruction plan. The court's decision will become legally binding on 19 December 2025, unless the decision is appealed to the Svea Court of Appeal before that date. The debt settlement in the reconstruction plan is conditional upon the share issues in the plan, and vice versa. If the share issues under the reconstruction plan are not completed by the last banking day of the month that falls two months after the reconstruction plan becomes legally binding,...

Peptonic Medical AB (publ) (“the Company”) announces that a plan hearing was held today at Uppsala District Court. During the hearing, the reconstruction plan was presented, and relevant parties had the opportunity to provide input and vote on the plan. The court's decision on whether the reconstruction plan can be adopted is expected tomorrow, Friday November 28, 2025. At the hearing, the reconstruction administrator and the Company presented the reconstruction plan. Parts of this presentation have, as previously announced, been published on the Company's website, www.peptonicmedical.se....

Peptonic Medical AB (publ) (“the Company”) announces current sales figures in connection with the plan hearing being held today at 10:00 AM at the Uppsala District Court. During the hearing, the reconstruction administrator and the Company will present the reconstruction plan. Parts of this presentation, including sales figures for October 2025 and accumulated for the period January through October 2025, have now been published on the Company's website. Current sales for October 2025 amount to 2,4 MSEK and for the period January to October 2025 amount to SEK 13.6 million, compared with the...

The press release announced today at 13:00 CET was referring to a previous press release that Uppsala District Court has approved the Company's request to extend its ongoing corporate reconstruction, the correct press release is that Svea Court of Appeal has rejected the Swedish Tax Agency's request to terminate the Company's corporate restructuring. Full press release below. Peptonic Medical AB (publ) (“the Company”) announces that today the Svea Court of Appeal has rejected the Swedish Tax Agency's request to terminate the Company's corporate restructuring. The Court of Appeal has...

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Uppsala District Court today, on 19 September 2025, has approved the Company's request to extend its ongoing corporate reconstruction by three months, until 16 December 2025. The purpose of the extension is to finalize the reconstruction plan and apply for a plan hearing in accordance with the Swedish Corporate Reconstruction Act. The Company intends to submit the reconstruction plan to relevant parties and apply for a plan hearing in the coming weeks, no later than the end of September 2025.   For further...

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) has received part of the first order under the recently signed strategic distribution agreement with US-based Joylux Inc. The order relates to the Company's product VagiVital AktivGel and amounts to USD 126,000. Work on design and artwork under the Joylux brand has commenced. Joylux is a well-established player in women's intimate self-care during and after menopause, with a strong brand, broad market presence, and an engaged community. Joylux offers effective intimate care products and innovative digital solutions that enhance women's...

Peptonic Medical AB (publ) (“the Company” or “Peptonic”) announces that the plan meeting in the Company's corporate reorganization will be held on 27 November 2025 at 10:00 a.m. On 23 October 2025, the Company published the reorganization plan in its ongoing corporate reorganization (the “Reorganization Plan”), which is also attached in full to this press release. On 24 October 2025, the Company requested that the District Court of Uppsala proceed with a hearing on the Reorganization Plan, a so-called plan negotiation. The District Court of Uppsala has today decided that the plan meeting,...

Peptonic Medical AB (publ) (the “Company”) announces the reconstruction plan in the Company's ongoing corporate restructuring (the “Reconstruction Plan”). The Reconstruction Plan has today been sent to relevant parties, and the Company intends to request that the District Court of Uppsala promptly schedule a hearing on the plan (a so-called plan negotiation). The Reconstruction Plan includes, among other things, a description of the Company's proposals for debt settlement and proposed resolutions regarding: (i) reduction of share capital without cancellation of shares for allocation to...